Prophylactic Anticoagulation in Patients With Pancreatic Adenocarcinoma: A Single Tertiary Care Center Retrospective QI Project
Authors:
Open Access
- 30 December 2022
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (1) , 137-141
Abstract
Background/Aim: A well-known complication of pancreatic adenocarcinoma (PDAC) is venous thromboembolism (VTE). The Khorana score is used as a tool to help determine the role of primary prophylaxis (PPx) in cancer patients with VTE. This study compared outcomes in PDAC patients who received primary PPx (anticoagulation) versus those who did not. Patients and Methods: PDAC patients from 2017-2019 at Allegheny General Hospital were retrospectively reviewed. Descriptive statistics were presented via medians with interquartile ranges for continuous variables and percentages for categorical variables. Predictors of VTE development were determined using univariable and multivariable logistic regression models. T-tests and Chi-square tests were used to compare means and percentages, respectively. Results: A total of 102 patients with full VTE PPx data were reviewed. At least one VTE event was identified in 29 patients (28.2%). A total of 4 out of these 29 patients (13.8%) were on PPx anticoagulation. Death secondary to VTE occurred in one patient without PPx. Two (2.0%) patients experienced bleeding events of those prescribed VTE PPx. On univariable analysis, stage IV disease, planned surgery, and unresectable disease were predictors of VTE development. On multivariate analysis, total pancreatectomy was a predictor of VTE development. There was no difference in average time to progression amongst patients who had developed VTE versus those who did not. Conclusion: The Khorana score for VTE PPx in PDAC patients in underutilized.Keywords
This publication has 15 references indexed in Scilit:
- Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI studyCancer Medicine, 2020
- Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With OutcomesGastroenterology, 2020
- 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerThe Lancet Oncology, 2019
- The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issuesBritish Journal of Cancer, 2019
- Apixaban to Prevent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2019
- Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective studyBMC Cancer, 2018
- Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort studyThrombosis Research, 2017
- High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort studyPancreatology, 2017
- The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancerThrombosis Research, 2017
- Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyJournal of Thrombosis and Haemostasis, 2007